Imago Biosciences is a privately-held biotechnology company focused on malignant and life-threatening diseases of the bone marrow. The initial clinical focus is on myeloproliferative neoplasm (MPN) disorders including myelofibrosis, essential thrombocythemia and polycythemia vera.
Our investors include a fund managed by Blackstone Life Sciences Group, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, Greenspring Associates, HighLight Capital, Xeraya Capital, and Pharmaron, along with strategic investors. Together they are committed to helping Imago advance our research and development programs adding value each step of the way.
Imago has a team of dedicated professionals who have proven their ability to advance product development in an effective, thoughtful and efficient manner. This, along with its exciting research in areas of unmet need, is what has made Imago a compelling investment opportunity.
Blackstone Life Science